[1] Davies, M., Færch, L., Jeppesen, O.K., Pakseresht, A., Pedersen, S.D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T.A. and Lingvay, I. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), pp.971–984. https://pubmed.ncbi.nlm.nih.gov/33667417/
[2] Singh, G., Krauthamer, M. and Bjalme-Evans, M. (2021). Wegovy (semaglutide): a new weight loss drug for chronic weight management. Journal of Investigative Medicine, p.jim-2021-001952. https://jim.bmj.com/content/70/1/5
[3] Commissioner, O. of the (2021). FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014. [online] FDA. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014.